A citation-based method for searching scientific literature


List of co-cited articles
1092 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
C Warren Olanow, Olivier Rascol, Robert Hauser, Paul D Feigin, Joseph Jankovic, Anthony Lang, William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi,[...]. N Engl J Med 2009
557
57



A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Olivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, Joseph Jankovic, Anthony Lang, J William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa,[...]. Lancet Neurol 2011
147
25


Levodopa and the progression of Parkinson's disease.
Stanley Fahn, David Oakes, Ira Shoulson, Karl Kieburtz, Alice Rudolph, Anthony Lang, C Warren Olanow, Caroline Tanner, Kenneth Marek. N Engl J Med 2004
24




Selegiline slows the progression of the symptoms of Parkinson disease.
S Pålhagen, E Heinonen, J Hägglund, T Kaugesaar, O Mäki-Ikola, R Palm. Neurology 2006
184
17

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Ira Shoulson, David Oakes, Stanley Fahn, Anthony Lang, J William Langston, Peter LeWitt, C Warren Olanow, John B Penney, Caroline Tanner, Karl Kieburtz,[...]. Ann Neurol 2002
192
16

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Robert A Hauser, Mark F Lew, Howard I Hurtig, William G Ondo, Joanne Wojcieszek, Cheryl J Fitzer-Attas. Mov Disord 2009
98
15

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Robert A Hauser, Dee Silver, Azhar Choudhry, Eli Eyal, Stuart Isaacson. Mov Disord 2014
36
41

Pharmacological treatment of Parkinson disease: a review.
Barbara S Connolly, Anthony E Lang. JAMA 2014
738
15

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
C Warren Olanow, Robert A Hauser, Joseph Jankovic, William Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi, Eldad Melamed, Eli Eyal,[...]. Mov Disord 2008
121
14

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
A H V Schapira, F Stocchi, R Borgohain, M Onofrj, M Bhatt, P Lorenzana, V Lucini, R Giuliani, R Anand. Eur J Neurol 2013
70
20

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Rupam Borgohain, J Szasz, P Stanzione, C Meshram, M Bhatt, D Chirilineau, F Stocchi, V Lucini, R Giuliani, E Forrest,[...]. Mov Disord 2014
153
14

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Rupam Borgohain, Jozsef Szasz, Paolo Stanzione, Chandrashekhar Meshram, Mohit H Bhatt, Dana Chirilineau, Fabrizio Stocchi, Valentina Lucini, Rodolfo Giuliani, Emma Forrest,[...]. Mov Disord 2014
141
14

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Matthew B Stern, Kenneth L Marek, Joseph Friedman, Robert A Hauser, Peter A LeWitt, Daniel Tarsy, C Warren Olanow. Mov Disord 2004
85
15


Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Richard Gray, Natalie Ives, Caroline Rick, Smitaa Patel, Alastair Gray, Crispin Jenkinson, Emma McIntosh, Keith Wheatley, Adrian Williams, Carl E Clarke. Lancet 2014
191
13


A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
P Barone, G Santangelo, L Morgante, M Onofrj, G Meco, G Abbruzzese, U Bonuccelli, G Cossu, G Pezzoli, P Stanzione,[...]. Eur J Neurol 2015
59
22

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.
Anthony H V Schapira, Michael P McDermott, Paolo Barone, Cynthia L Comella, Stefan Albrecht, Helen H Hsu, Daniel H Massey, Yoshikuni Mizuno, Werner Poewe, Olivier Rascol,[...]. Lancet Neurol 2013
107
12

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E Lang, C Warren Olanow. Ann Neurol 2010
210
12

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
M Flint Beal, David Oakes, Ira Shoulson, Claire Henchcliffe, Wendy R Galpern, Richard Haas, Jorge L Juncos, John G Nutt, Tiffini Smith Voss, Bernard Ravina,[...]. JAMA Neurol 2014
199
12

The effect of deprenyl and levodopa on the progression of Parkinson's disease.
C W Olanow, R A Hauser, L Gauger, T Malapira, W Koller, J Hubble, K Bushenbark, D Lilienfeld, J Esterlitz. Ann Neurol 1995
275
12

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hasmet A Hanagasi, Hakan Gurvit, Pınar Unsalan, Hilal Horozoglu, Nese Tuncer, Aynur Feyzioglu, Dilek Ince Gunal, Gorsev G Yener, Raif Cakmur, Huseyin A Sahin,[...]. Mov Disord 2011
70
15

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
J M Rabey, I Sagi, M Huberman, E Melamed, A Korczyn, N Giladi, R Inzelberg, R Djaldetti, C Klein, G Berecz. Clin Neuropharmacol 2000
118
11

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Fabrizio Stocchi, Rupam Borgohain, Marco Onofrj, Anthony H V Schapira, Mohit Bhatt, Valentina Lucini, Rodolfo Giuliani, Ravi Anand. Mov Disord 2012
79
13


Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Alan L Whone, Ray L Watts, A Jon Stoessl, Margaret Davis, Sven Reske, Claude Nahmias, Anthony E Lang, Olivier Rascol, Maria J Ribeiro, Philippe Remy,[...]. Ann Neurol 2003
601
11

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Susan H Fox, Regina Katzenschlager, Shen-Yang Lim, Brandon Barton, Rob M A de Bie, Klaus Seppi, Miguel Coelho, Cristina Sampaio. Mov Disord 2018
320
11

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
C Warren Olanow, Karl Kieburtz, Olivier Rascol, Werner Poewe, Anthony H Schapira, Murat Emre, Helena Nissinen, Mika Leinonen, Fabrizio Stocchi. Mov Disord 2013
270
10

Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
S Pålhagen, E H Heinonen, J Hägglund, T Kaugesaar, H Kontants, O Mäki-Ikola, R Palm, J Turunen. Neurology 1998
103
10


Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Michel Panisset, Jack J Chen, Sean H Rhyee, Jill Conner, Julie Mathena. Pharmacotherapy 2014
31
32

SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
H Przuntek, B Conrad, J Dichgans, P H Kraus, P Krauseneck, G Pergande, U Rinne, K Schimrigk, J Schnitker, H P Vogel. Eur J Neurol 1999
75
13


Parkinson's disease.
Lorraine V Kalia, Anthony E Lang. Lancet 2015
10

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
Susan H Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G Goetz, Cristina Sampaio. Mov Disord 2011
365
9

Epidemiology of Parkinson's disease.
Lonneke M L de Lau, Monique M B Breteler. Lancet Neurol 2006
9

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Robert G Holloway, Ira Shoulson, Stanley Fahn, Karl Kieburtz, Anthony Lang, Kenneth Marek, Michael McDermott, John Seibyl, William Weiner, Bruno Musch,[...]. Arch Neurol 2004
402
9

Safinamide: from molecular targets to a new anti-Parkinson drug.
C Caccia, R Maj, M Calabresi, S Maestroni, L Faravelli, L Curatolo, P Salvati, R G Fariello. Neurology 2006
136
9

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, Jennifer Fine, Janos Nikl, Krystyna Honczarenko, Peter Dioszeghy, Dennis Hill, Tim Anderson, Vilho Myllyla,[...]. Mov Disord 2011
278
9

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
Christopher G Goetz, Barbara C Tilley, Stephanie R Shaftman, Glenn T Stebbins, Stanley Fahn, Pablo Martinez-Martin, Werner Poewe, Cristina Sampaio, Matthew B Stern, Richard Dodel,[...]. Mov Disord 2008
9

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A J Hughes, S E Daniel, L Kilford, A J Lees. J Neurol Neurosurg Psychiatry 1992
8

Long-term efficacy of rasagiline in early Parkinson's disease.
Mark F Lew, Robert A Hauser, Howard I Hurtig, William G Ondo, Joanne Wojcieszek, Tamar Goren, Cheryl J Fitzer-Attas. Int J Neurosci 2010
24
33




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.